Evidence map›Paper›PMID 28101801›Full record

ArticlePathology oncology research : POR2017

Identification of Changes in the Human Papilloma Virus 16 (HPV16) Genome During Early Dissemination of Cervical Cancer Cells May Complement Histological Diagnosis of Lymph Node Metastasis.

Anirban Roychowdhury, Sudip Samadder, Md Saimul Islam, Kalyansree Chaudhury, Anup Roy, Dipanwita Banerjee, Ranajit Mandal, Partha S Basu, Susanta Roychoudhury, Chinmay Kumar Panda

Abstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Vimentin Is Required for Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell-Cancer-Associated Fibroblast Interactions during Collective Invasion.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Anirban RoychowdhuryDepartment of Oncogene Regulation, Chittaranjan National Cancer Institute, Kolkata, India.
Sudip SamadderDepartment of Oncogene Regulation, Chittaranjan National Cancer Institute, Kolkata, India.
Md Saimul IslamDepartment of Oncogene Regulation, Chittaranjan National Cancer Institute, Kolkata, India.
Kalyansree ChaudhuryDepartment of Gynecology and Obstetrics, Burdwan Medical College, Burdwan, West Bengal, India.
Anup RoyDepartment of Pathology, North Bengal Medical College and Hospital, Siliguri, West Bengal, India.
Dipanwita BanerjeeDepartment of Gynecology Oncology, Chittaranjan National Cancer Institute, Kolkata, India.
Ranajit MandalDepartment of Gynecology Oncology, Chittaranjan National Cancer Institute, Kolkata, India.
Partha S BasuIndia Screening Group (SCR), Early Detection and Prevention Section (EDP), International Agency for Research on Cancer (IARC), World Health Organization (WHO), Lyon, France.
Susanta RoychoudhurySaroj Gupta Cancer Centre & Research Institute, Kolkata, India.
Chinmay Kumar PandaDepartment of Oncogene Regulation, Chittaranjan National Cancer Institute, Kolkata, India. ckpanda.cnci@gmail.com.
Chittaranjan National Cancer Institute · INBurdwan Medical College & Hospital · INCentre International de Recherche sur le Cancer · FRNorth Bengal Medical College and Hospital · INSaroj Gupta Cancer Centre & Research Institute · IN

Funding

Department of Science and Technology (DST), Government of India SR/SO/HS-116/2007University Grants Commission (UGC), Government of India Sr No. 2121130723World Health Organization 001
6 · The paper itself

Abstract

Cancer of the uterine cervix (CACX) is one of the most common carcinoma affecting women worldwide. During treatment, histologically lymph node (LN) metastasis and presence of HPV DNA in blood plasma act as a major prognostic factor. Despite the lack of apparent LN involvement, some early-invasive CACX patients have shown recurrences and poor survival. This is suggestive of undetected early dissemination of cancer cells characterized by presence of HPV DNA in histologically non-metastatic LNs which finally progresses into histologically visible metastasis. This present study investigated the status and origin of HPV genome during early dissemination by molecular analysis in primary tumor (PT), histologically non-metastatic pelvic lymph nodes (LNs) and blood plasma (BP) of same patient. First, CACX patients showing signs of early dissemination was identified by detection of HPV in PT (n = 22) and their corresponding histologically non-metastatic pelvic LNs (n = 45) and BP (n = 18) followed by typing of HPV16/18. This was followed by comparative analysis of the physical, copy number and methylation (enhancer/early/late) status of HPV16 genome present in LNs and BP with that of PT. Our study revealed for the first time that the HPV16 genome were frequently present in the integrated form though the copy number was low in both non-metastatic LNs and BP. However, the methylation pattern of PT was discordant with that of corresponding LNs and BP in majority of the cases. Critical assessment of HPV16 profiles established that the presence of hrHPV may be due to the early dissemination of PT cells having significant pathological implications.

Indexed as

Carcinoma, Squamous CellDNA, ViralFemaleHuman papillomavirus 16HumansLymphatic MetastasisLymph NodesPapillomavirus InfectionsUterine Cervical NeoplasmsDNA, ViralDisseminated tumor cells (DTCs)HPV16 integrationHPV16 methylationHuman papillomavirus (HPV) type 16Lymph node metastasisUterine cervical carcinoma

Identifiers

PMID28101801
OpenAlexW2579092978

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.